Inovio Pharmaceuticals (NASDAQ: INO) was among the first to start clinical trials on a coronavirus vaccine candidate. But the biotech company wasn’t among the first to cross the vaccine race finish line. The U.S. Food and Drug Administration (FDA) last fall placed one of Inovio’s vaccine trials on a partial clinical hold, and the program fell behind.
Now, Inovio’s candidate is in phase 2. The clinical-stage biotech company also is working on a next-generation vaccine. And a recent statement by White House chief medical advisor Dr. Anthony Fauci may mean good news for one of these programs.